Rakovina Therapeutics Inc (TSE:RKV) has released an update.
Rakovina Therapeutics Inc. has announced collaborations and advisory board appointments aimed at advancing cancer therapies, alongside presenting promising preclinical data for their kt-3000 series targeting rare cancers. Despite a net loss for the year 2023, the company maintains a positive working capital and continues to invest heavily in research and development. These strategic moves and financial results reflect the company’s commitment to innovation in DNA-damage response technologies for cancer treatment.
For further insights into TSE:RKV stock, check out TipRanks’ Stock Analysis page.
